HIV risk behaviors during pharmacologic treatment for opioid dependence: A comparison of levomethadyl acetate hydrochloride, buprenorphine, and methadone

Lott, David C.; Strain, Eric C.; Brooner, Robert K.; Bigelow, George E.; Johnson, Rolley E.

doi:10.1016/j.jsat.2006.04.005

Cited by 30 publications

(27 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,3 The present study found a significantly greater reduction in drug injection from baseline to follow-up for the IM condition compared to the WL condition. Despite this finding, the condition×time interaction for the overall ARA drug use behavior score was nonsignificant, perhaps because 60.2% of the study sample was non-injectors and the injectors reported low levels of risky injection practices at baseline.…”

Section: Discussionmentioning

confidence: 42%

See 1 more Smart Citation

Impact of Interim Methadone Maintenance on HIV Risk Behaviors

et al. 2010

View full text Add to dashboard Cite

The extent to which interim methadone (IM) without counseling reduces HIV risk behavior has not been reported. The AIDS Risk Assessment scale was administered at baseline and 4-month follow-up to 319 adult heroin-dependent participants randomly assigned to IM or waiting list. On an intent-to-treat basis, there was a significantly greater reduction in drug injection and unprotected sex while high from baseline to follow-up, favoring the IM condition. Remedying the shortage of methadone capacity through the expansion of IM would be a worthwhile approach to reducing the spread of HIV infection.

show abstract

Section: Discussionmentioning

confidence: 42%

“…1 There are limited data from RCTs of standard methadone treatment which incorporated an HIV risk measure 2,3 and even less from trials of methadone alone.…”

Section: Introductionmentioning

confidence: 99%

Impact of Interim Methadone Maintenance on HIV Risk Behaviors

et al. 2010

View full text Add to dashboard Cite

show abstract

“…A further study examining patients receiving either methadone, buprenorphine or levomethadyl acetate hycrochloride (LAAM) in a substance abuse treatment program revealed declines in drug-related risk behaviors in all three treatment groups but a reduction in sexual risk behaviors only in the methadone group. (Lott, Strain, Brooner, Bigelow, & Johnson, 2006) There are limitations to our study. All data on HIV risk behaviors were collected by self-report and without accompanying HIV serostatus determination and therefore do not provide information on actual HIV transmission.…”

Section: Discussionmentioning

confidence: 89%

Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors

Sullivan

Moore

Chawarski

et al. 2008

Journal of Substance Abuse Treatment

View full text Add to dashboard Cite

Methadone treatment reduces HIV risk but the effects of primary care-based buprenorphine/naloxone on HIV risk are unknown. The purpose of the current study was to determine whether primary carebased buprenorphine/naloxone was associated with decreased HIV risk behavior. We conducted a longitudinal analysis of 166 opioid dependent persons (129 men and 37 women) receiving buprenorphine/naloxone treatment in a primary care clinic. We compared baseline, 12 and 24-week overall, drug-related and sex-related HIV risk behaviors using the AIDS/HIV Risk Inventory (ARI). Buprenorphine/naloxone treatment was associated with significant reductions in overall and drugrelated ARI scores from baseline to 12 and 24-weeks. Intravenous drug use in the past 3 months was endorsed by 37%, 12%, and 7%, of patients at baseline, 12 weeks and 24 weeks, respectively; p < 0.001. Sex while you or your partner were "high" was endorsed by 64%, 13%, and 15% of patients at baseline, 12 weeks and 24 weeks, respectively; p<0.001. Inconsistent condom use during sex with a steady partner was high at baseline and did not change over time. We conclude that primary carebased buprenorphine/naloxone treatment is associated with decreased drug-related HIV risk but additional efforts may be needed to address sex-related HIV risk when present. (ClinicalTrials.gov number, NCT00023283).

show abstract

“…Therefore, the Chinese government initiated methadone maintenance in 2004 with the hope of enhancing treatment effectiveness and reducing HIV risks among IDUs -the most afflicted subgroup in this country. These positive findings may encourage the Chinese government to scale up the MMT program and also to look at other evidence-based pharmacological interventions, such as buprenorphine and levo-alpha acetyl methadol (Lott, Strain, Brooner, Bigelow, & Johnson, 2006), which still are not available in China. Drug addiction and IDU are still increasing at alarming rates in many developing countries, especially in Eastern and Central Europe and Asia, but treatment programs are lacking or are only at the initiation phase (UNAIDS, 2006).…”

Section: Discussionmentioning

confidence: 98%